Skip to main content
OpenTrials
Completed

NCT Number: NCT01343407

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

This was a 2-part study in participants with allergen-induced asthma. It included a procedural pilot component (Part 1). Part 1 tested the key procedures and timing of Part 2; no study drug was administered during Part 1. Part 2 included a pre-randomization placebo run-in (Period 1) and 3 treatment periods (Periods 2, 3, and 4) during which participants were randomized to receive double-blind placebo, MK-1029 60 mg or MK-1029 500 mg in a crossover design. The treatment periods were followed by a minimum 21-day washout. Part 2 assessed allergen-induced sputum eosinophils and allergen-induced late asthmatic response (LAR) compared to placebo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Parts 1 and 2

  • Is male or a female of non-childbearing potential
  • Has a history of allergen-induced asthma for at least 6 months
  • Is judged to be in good health (other than asthma)
  • Is able to perform reproducible pulmonary function testing
  • Has a positive methacholine challenge test on Day -1
  • Has an allergic response to house dust mite allergen as defined by positive skin prick test
  • Is a nonsmoker and/ or has not used nicotine or nicotine-containing products for at least 12 months
  • Has body mass index (BMI) ≥17 kg/m^2, but ≤33 kg/m^2

Part 2 only

  • Must demonstrate a dual airway response to an allergen challenge in Period 1, decrease in FEV1 of at least 20% 0 to 2 hours after allergen challenge for early asthmatic response (EAR) and a positive late asthmatic response (LAR) to an inhaled allergen challenge as defined by a bronchoconstrictive response of at least 15% reduction in FEV1 3 to 8 hours after allergen challenge
  • Can tolerate sputum induction and produce adequate sputum

Exclusion criteria

Parts 1 and 2

  • Has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses additional risk to the participant
  • Has recent (4 weeks) or ongoing upper or lower respiratory tract infection
  • Is unable to refrain from or anticipates the use of any medication other than the ones permitted in this study
  • Has taken oral, intramuscular, intra-articular, high-potency topical or orally inhaled corticosteroids within 8 weeks
  • Has taken the following medications outside the washout margins: nasal corticosteroids and anti-leukotrienes within 3 weeks; inhaled long-acting β2-agonists, long-acting antihistamines (e.g., loratadine, sustained-release agents), intra-nasal anticholinergics over-the-counter decongestants within 1 week; short-acting oral decongestants, short-acting antihistamines (e.g., chlorpheniramine) within 48 hours
  • Consumes excessive amounts of alcohol or caffeinated beverages
  • Has had major surgery, donated or lost 1 unit of blood or participated in another investigational study within 3 months
  • Has a history of severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
  • Is a nursing mother
  • Has a history of receiving anti-immunoglobulin E (IgE) or immunotherapy
  • Has a history of serious allergies to drugs or a history of hypersensitivity to mometasone furoate or any of its inactive ingredients such as lactose, or inhaled salbutamol, antihistamines, or any

other potential asthma/anaphylaxis rescue medication

Part 2 only

  • Has a decline in FEV1 of 70% or greater from the post allergen diluent baseline and/or FEV1 <1.0L or has symptomatic drop in FEV1 associated with shortness of breath unresolved with bronchodilators within a reasonable timeframe (60 minutes) after the allergen challenge study in Period 1

Treatment and study plan

MK-1029 10 mg

Drug

Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design

MK-1029 100 mg

Drug

Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design

Placebo for MK-1029 10 mg

Drug

Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design."

Placebo for MK-1029 100 mg

Drug

Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design

Primary outcomes

  1. Percent Change From Baseline in Percent (%) Eosinophils in Induced Sputum At 8 Hours Post Allergen

    Time frame: Baseline (Day -1) and Day 5 (8 hours after allergen challenge in each treatment period)

    The effect of MK-1029 on the reduction of percent (%) sputum eosinophils following allergen challenge with standardized cat pelt or hair (CPH) allergen extract was assessed. Baseline % eosinophils were measured before treatment (and pre-allergen challenge) on Day -1. The change from baseline in allergen-induced % sputum eosinophils at 8 hr post allergen challenge testing on Day 5 was analyzed using a repeated measures linear mixed effects model with treatment, period, time, time-by-treatment interaction as fixed factors, and participant as a random factor. Outcome Measure 6 shows % eosinophil values at baseline.

  2. Forced Expiratory Volume in One Second (FEV1) From 3 to 8 Hours Postdose (AUC3-8hr) During the Late Asthmatic Response (LAR)

    Time frame: From 3 to 8 hours after allergen challenge on Day 5 of each treatment period

    The effect of MK-1029 on the FEV1 AUC(3-8hr) during LAR was assessed. The unit of measure for an FEV1 AUC value is L*hr. The effect of treatment on LAR was assessed as the percent-fall in FEV1 AUC(3-8hr), evaluated by spirometry following allergen challenge on Day 5. The FEV1 AUC(3-8hr) during LAR was analyzed using a linear mixed effects model with treatment and period as fixed factors and participant as a random factor.

  3. Number of Participants With an Adverse Event (AE)

    Time frame: Up to 26 days in each treatment period

    The number of participants who had at least one adverse event (AE) during study treatment and follow-up was assessed. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.

  4. Number of Participants Discontinuing Treatment Due to an AE

    Time frame: Up to 5 days in each treatment period

    The number of participants who discontinued study treatment due to an AE was assessed. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.

Secondary outcomes

  1. Percent Inhibition of the Expression of Cluster of Differentiation (CD)11b on Blood Eosinophils

    Time frame: Baseline (Day -1, predose), 24 hours after allergen challenge on Day 5 in each treatment period

    The concentration of CD11b in whole blood samples was assessed. The percent-inhibition of CD11b (a cell-surface biomarker on activated eosinophils) was assessed following inhaled allergen challenge on Day 5. Inhibition of CD11b expression was assessed by analyzing the % inhibition of CD11b expression from baseline (Day -1) using a linear mixed-effects model with period, treatment, time, and treatment by time as fixed terms and subject as a random term. Outcome Measure 7 shows CD11b expression values at baseline.

Other outcomes

  1. Baseline (Pre-Treatment) Percent (%) Eosinophils

    Time frame: Baseline (Day -1), pre-antigen challenge

    Baseline values of the percent (%) sputum eosinophils were measured pre-antigen challenge on Day -1. The baseline % eosinophil values were provided to assess the change from baseline after treatment.

  2. Baseline Expression of Cluster of Differentiation (CD)11b on Blood Eosinophils

    Time frame: Day 1, predose

    Baseline values for the antibody-specific expression of CD11b in whole blood samples, as obtained by flow cytometry, were obtained. The baseline CD11b values were obtained before treatment with MK-1029 60 mg, MK-1029 500 mg, or placebo, and were used to assess the effects of treatment.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Two-Part, Multicenter, Randomized, Clinical Trial to Study the Effects of Multiple Doses of MK-1029 on the Late Asthmatic Response to Lung Allergen Challenge in Asthmatics

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Apr 28, 2011
Registry last updated
Mar 1, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.